| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 978,200 | 687,900 | 356,400 | 3,785,400 |
| Depreciation and amortization | 113,900 | 74,700 | 36,600 | 112,600 |
| Non-cash operating lease cost | 19,300 | 12,500 | 6,100 | 21,600 |
| Stock-based compensation (note 9) | 118,900 | 77,700 | 40,200 | 130,600 |
| Gain on sale of business | 0 | - | - | 3,337,400 |
| Intangible assets impairment charges | 40,000 | - | - | - |
| Loss (gain) on investments, net | - | - | -12,500 | - |
| Change in fair value of contingent consideration liabilities | -12,500 | - | - | 0 |
| Deferred income taxes | 63,200 | 45,200 | 24,300 | 224,900 |
| Gain on remeasurement of previously held interest upon acquisition | 0 | - | - | 24,600 |
| Loss on impairment | 47,100 | 47,100 | - | - |
| Other | -2,300 | -8,300 | -3,600 | -2,700 |
| Accounts and other receivables, net | 55,400 | 68,600 | 43,700 | -15,300 |
| Inventories | -39,700 | -41,500 | 100 | 204,900 |
| Accounts payable and accrued liabilities | 226,400 | 300 | -103,400 | 92,600 |
| Income taxes | -199,400 | -189,200 | 51,200 | 301,800 |
| Prepaid expenses and other current assets | 17,500 | 3,300 | -10,600 | -27,400 |
| Intellectual property agreement accrual | -61,700 | -49,200 | -36,700 | -24,300 |
| Long-term prepaid royalties (note 3) | - | - | - | -6,200 |
| Other | 31,800 | 23,900 | 28,600 | 10,300 |
| Net cash provided by operating activities | 1,144,300 | 570,600 | 280,400 | 669,800 |
| Capital expenditures | 162,800 | 105,300 | 56,000 | 202,600 |
| Investments in unconsolidated affiliates | 49,800 | 48,300 | - | - |
| Purchases of held-to-maturity investments (note 5) | 43,200 | 18,800 | 12,800 | 36,300 |
| Proceeds from held-to-maturity investments (note 5) | 54,200 | 32,000 | 17,700 | 50,400 |
| Purchases of available-for-sale investments (note 5) | 2,265,200 | 1,258,800 | 634,500 | 518,800 |
| Proceeds from available-for-sale investments (note 5) | 2,109,400 | 1,439,700 | 827,900 | 539,100 |
| Investments in intangible assets | 0 | 0 | 0 | 25,400 |
| Proceeds from sale of business | - | - | - | 3,927,400 |
| Payment for working capital adjustment and sale of product group (note 4) | 36,300 | 36,300 | 36,300 | - |
| Business combinations, net of cash | 0 | - | - | 763,600 |
| Payment for acquisition options | 19,600 | 17,000 | 3,000 | 16,200 |
| Issuances of notes receivable | 93,400 | 70,600 | 17,800 | 28,000 |
| Other | 7,900 | 3,400 | -100 | 36,400 |
| Net cash (used in) provided by investing activities | -514,600 | -86,800 | 85,300 | 2,889,600 |
| Purchases of treasury stock | 852,800 | 264,100 | 258,600 | 1,059,300 |
| Equity forward contract related to accelerated share repurchase agreement (note 10) | 0 | 50,000 | 50,000 | 100,000 |
| Purchase of remaining noncontrolling interest in subsidiary (note 6) | 233,700 | - | - | - |
| Proceeds from stock plans | 141,800 | 107,100 | 49,900 | 150,900 |
| Other | -700 | 1,700 | 700 | -3,200 |
| Net cash used in financing activities | -945,400 | -205,300 | -258,000 | -1,011,600 |
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | -48,300 | -47,300 | -17,700 | -12,400 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -364,000 | 231,200 | 90,000 | 2,535,400 |
| Cash and cash equivalents at beginning of period | 3,058,800 | 3,058,800 | 3,058,800 | 1,148,000 |
| Cash and cash equivalents at end of period | 2,694,800 | 3,290,000 | 3,148,800 | 3,683,400 |
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)